ANZCTR search results

Diabetes has been understudied in the substance use population and there have been strong calls to address this paucity. People with substance use problems are at high risk of developing T2D yet screening and education is not integrated into routine care. The aim of the proposed study is to assess the effectiveness of the T2D risk communication tool on T2D risk perceptions and behavioural intentions among people with alcohol or other drug problems (i.e. participants who are receiving treatment/support for substance use problems). Specifically, the study will examine whether personalised T2D risk feedback is more effective in improving risk perceptions and increasing health behavioural intentions to reduce T2D risk compared to an active control group. We hypothesise that participants receiving the personalised T2D risk feedback will report significantly more accurate T2D risk perceptions and greater behavioural intentions compared to participants in the active control group.

Cognitive-behavioural therapy approaches for eating disorders (CBT-ED) are typically 20 sessions duration and can be challenging to access for consumers due to the time, cost and difficulty finding therapists who have the required expertise. While shorter guided-self interventions (GSH-CBT) designed to be used by non-experts have existed for a while as a first option in a stepped care approach, it has only been recently that a 10-session version of CBT-ED (CBT-T) has been available. This study compares these two brief CBT interventions to determine if either one is superior in treating non-underweight individuals with eating disorders.

STOP is intended to be a small pilot study conducted in a specialised paediatric emergency department (ED) examining the effect of giving the medication tranexamic acid or 'TXA' via a nebuliser on children aged 3-16y ears who come to the ED with throat bleeding after tonsillectomy surgery. We intend to study whether nebulised TXA is a safe and effective alternative to intravenous TXA, which is currently part of the standard treatment for this condition in the institution involved. Each child presenting to our ED with bleeding following tonsillectomy surgery will be screened for suitability, considered for enrolment and approached for consent to participate. Half of the patients will be allocated to a single initial dose of nebulised TXA and half will be allocated the standard single dose intravenous TXA treatment. We will grade the severity of bleeding from the throat on each patient firstly on their arrival to the ED and again 15 minutes after the TXA has been administered. We will also capture data concerning the timing of treatment, the acceptability and tolerance to nebulised TXA for this condition and information regarding the patient's episode of hospital care. The results will help us understand whether nebulised TXA is tolerated, easy to administer, its safety profile and its impact on post tonsillectomy bleeding in comparison to IV TXA treatment. We will also seek to establish if there is any evident differences in subsequent hospital stay and medium term adverse effects.

The purpose of this study is to review the use of Vinorelbine as a chemotherapy treatment option in patients post immunotherapy for metastatic non-small cell lung cancer (NSCLC). Who is it for? You may be eligible for this study if you, have received immunotherapy for metastatic NSCLC and are a patient at one of the participating sites. Study details Participants in this study will continue to receive routine clinical care, which will not be impacted by involvement in this study. Enrolled participants will have clinical data collected at one time point from their medical record. Data will be collected on the tolerability and duration of Vinorelbine chemotherapy when used following immunotherapy treatment in patients with metastatic NSCLC. It is hoped this research will offer insight into the use of Vinorelbine as a potentially beneficial treatment option for patients with metastatic NSCLC in the post immunotherapy setting.

A randomised double-blind placebo-controlled study to evaluate the effect of curcumin on BDNF levels in otherwise healthy adults. The aim of this study is to assess the effectiveness of a bioavailable form of curcumin on BDNF levels compared to a placebo in otherwise healthy adults aged between 18 and 40 years old.

The purpose of this study is to assess the safety, tolerability of the drug INCB086550 and assess how this drug acts in the body with and without food and in combination with other drugs. who is it for? You may be eligible for this study if you are a male or female, aged 18 to 55, and you are in good health with no existing conditions. Study Details In Cohort 1 all participants will receive a single dose of the drug (orally in a fasted (no food) or fed (med calorie food) condition in Periods 1 and 2 by random assignment. In Cohort 2 through 5 subjects will be dosed with INCB086550 in combination with other drugs specified earlier. It is hoped this research will provide information as to how this drug acts in the body in fed and fasted conditions and in combination with other drugs, results from the study will affect how patients with cancer use this medication

CALM-GUT study is an observational study that aims to evaluate cannabinoid based medicines as a potential therapy for reducing symptoms of irritable bowel syndrome (IBS). Patients over 18 years of age who attend Emerald Clinics for treatment of IBS symptoms with cannabinoid based medicines will be offered participation in the study. Patients are observed for 12 weeks, using a combination of validated questionnaires, self-reported symptoms, and regular follow up with a specialist GP or gastroenterologist. Baseline symptoms and responses to questionnaires will be compared to results after 12 weeks to determine if the treatment is safe and effective in this patient cohort.

This is a single center, open-label, study of rosuvastatin 140 mg ER capsules (LYN-047) to evaluate its safety, tolerability, and PK when administered as 2 weekly doses in healthy male and female volunteers.

Stroke is the third leading cause of death in Australia. Ischaemic stroke accounts for ~80% of all stroke cases and is caused by a narrowing or obstruction of the blood vessels resulting in oxygen and nutrient deprivation. Conventional post-stroke management involves combining pharmacotherapy and rehabilitative therapies. Nao Xin Qing (NXQ) is a TGA-approved product (AUSTL196297) in Australia. NXQ is a novel herbal formula made from the standardised extract of persimmon leaves. NXQ has been used clinically in China for numerous years in the treatment of apoplexy, coronary heart disease and enhance recovery from ischemic stroke. The aim of this randomised double-blind controlled study is to assess the clinical effectiveness of NXQ for ischaemic stroke patients during rehabilitation phase. This will provide preliminary data whether NXQ can be used as an effective treatment of ischaemic stroke recovery, to prevent recurrence of stroke and improve quality of life of stroke survivors.

To date, nutrition research in critical illness has focused on the acute early period of illness, when metabolic changes and catabolism occurs. However, despite much research, no large-scale randomised controlled trial (RCT) has demonstrated a clear benefit for nutrition interventions delivered early and for a short duration in the Intensive Care Unit (ICU). Limited work investigating nutrition in the post-ICU phase of illness has been conducted to date, but what is known consistently shows (across many different populations) that intake in this period is below clinician estimates. These shortfalls in nutrition adequacy across acute hospitalisation (and if these shortfalls continue to the sub-acute setting also), may have the potential to impact long-term recovery following critical illness although investigation in this area is lacking. The aim of this study is to describe the nutrition process of care in critically ill adult patients from ICU admission until discharge from inpatient rehabilitation. This study is a single-centre retrospective observational study conducted at an acute care hospital and subacute inpatient facility within Alfred Health, including adult patients aged 18 years and above, who had an ICU admission at The Alfred Hospital for more than 48 hours with discharge to Caulfield Hospital inpatient rehabilitation within 28 days during index hospitalisation admission.